Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery.

@article{Denis2016DropletDP,
  title={Droplet digital PCR of circulating tumor cells from colorectal cancer patients can predict KRAS mutations before surgery.},
  author={J{\'e}r{\^o}me Alexandre Denis and Alexia Patroni and Erell Guillerm and Dominique P{\'e}pin and Naoual Benali-Furet and Janine Wechsler and Gilles Manceau and Maguy Bernard and Florence Coulet and Annette K. Larsen and Mehdi Karoui and Jean-Marc Lacorte},
  journal={Molecular oncology},
  year={2016},
  volume={10 8},
  pages={
          1221-31
        }
}
In colorectal cancer (CRC), KRAS mutations are a strong negative predictor for treatment with the EGFR-targeted antibodies cetuximab and panitumumab. Since it can be difficult to obtain appropriate tumor tissues for KRAS genotyping, alternative methods are required. Circulating tumor cells (CTCs) are believed to be representative of the tumor in real time. In this study we explored the capacity of a size-based device for capturing CTCs coupled with a multiplex KRAS screening assay using droplet… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 27 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 56 REFERENCES

Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
VIEW 15 EXCERPTS
HIGHLY INFLUENTIAL

KRAS and BRAF mutation

B. Mostert, Y. Jiang, +16 authors J. W. Martens
  • 2013
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL